文献速递妇科

BRCA突变状态能否预测高级别浆液性卵巢癌患者铂类化疗相关血液学毒性

Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
PubMed 文献 · Gynecol Oncol · 2019-05-09

回顾性分析176例接受一线卡铂(AUC 5)联合紫杉醇175 mg/mq共6周期化疗的高级别浆液性卵巢癌患者,其中58例(33%)为BRCA1/2突变携带者。BRCA突变组血小板减少、贫血和中性粒细胞减少的发生率均显著高于非突变组,且粒细胞集落刺激因子注射和剂量延迟更常见。

要点

  • BRCA突变组血小板减少24% vs 非突变组5%(p<0.001)
  • BRCA突变组贫血21% vs 非突变组7%(p=0.006)
  • BRCA突变组中性粒细胞减少62% vs 非突变组27%(p≤0.001)

核心结论

  • 生殖系BRCA1/2突变与接受铂类化疗的卵巢癌患者更高的血液学毒性相关。

研究设计与样本

  • 回顾性研究,从数据库中选取已知BRCA突变状态并接受一线6周期卡铂(AUC 5)联合紫杉醇175 mg/mq化疗的高级别浆液性卵巢癌患者,共176例,其中BRCA1/2突变携带者58例(33%),非携带者118例(67%)。

主要发现

  • BRCA突变组血小板减少发生率24% vs 非突变组5%(p<0.001)。
  • BRCA突变组贫血发生率21% vs 非突变组7%(p=0.006)。
  • BRCA突变组中性粒细胞减少发生率62% vs 非突变组27%(p≤0.001)。
  • BRCA突变组粒细胞集落刺激因子注射率12% vs 非突变组1%(p<0.001),剂量延迟率19% vs 非突变组27%(p=0.005)。
  • 多因素分析显示BRCA突变组粒细胞集落刺激因子注射更频繁(OR 2.567,95%CI 1.136-5.798,p=0.035),剂量延迟更频繁(OR 3.860,95%CI 1.098-13.570,p=0.023)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate hematologic adverse effect profiles associated with frontline platinum-based chemotherapy in ovarian cancer patients according to BRCA 1/2 mutational status. METHODS: Patients with high-grade serous ovarian cancer and a known BRCA mutational status who received in frontline 6 cycles of Carboplatin (AUC 5) plus Paclitaxel 175 mg/mq were retrospectively selected from our databases. Hematologic toxicity profiles of BRCA mutated patients were compared to non-mutated patients, according to EORTC Common Terminology Criteria for Adverse Events (CTCAE_4.02). RESULTS: Totally, 176 women of whom 58 (33%) were BRCA1/2 mutation carriers - 40 BRCA1 (69%) and 18 (31%) BRCA2 mutations carriers - and 118 (67%) non-carriers were identified. A significant higher frequency of thrombocytopenia (24% vs 5%; p < 0.001), anemia (21% vs 7%; p = 0.006) and neutropenia (62% vs 27%; p ≤0.001) was observed in BRCA mutated patients, resulting in a higher percentage of granulocyte-colony stimulating growth factors injection (12% versus 1%, p < 0.001) and dose delay (19% versus 27%, p = 0.005). The multivariate analysis confirmed that granulocyte-colony stimulating growth factors injection and dose delay were statistically significantly more frequent in BRCA mutated patients (OR 2.567, 95% CI 1.136-5.798, p = 0.035; OR 3.860, 95% CI 1.098-13.570, p = 0.023). Finally, the total number of hematologic adverse events compared between the two groups of patients during the entire treatment period showed a substantial higher rate of hematologic adverse events in BRCA mutated population. CONCLUSIONS: Germline BRCA 1/2 mutations are associated with a higher hematologic toxicity in patients with ovarian cancer who underwent platinum-based chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Tomao F, Musacchio L, Di Mauro F, et al. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecol Oncol. 2019. PMID: 31079832. doi:10.1016/j.ygyno.2019.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。